(Danaher: Washington, DC) -- Danaher Corp. announces plans to launch its first AI-powered autonomous lab, designed to help researchers develop custom antibodies and other molecular tools faster and more efficiently.

Expected to operate at scale in early 2027, the lab will combine artificial intelligence, robotics, and technologies from several Danaher operating companies in one connected workflow. It’s the first step in a broader Danaher initiative to create smart instruments, integrated workflows, and autonomous labs that accelerate scientific research.

Danaher’s first AI-powered autonomous lab is designed to deliver:
• Speed: Up to eight times faster discovery of affinity reagents, helping researchers get from idea to breakthrough sooner
• Scale: Unlocking up to a tenfold increase in annual reagent generation, from tens to hundreds of reagents per year as the lab scales
• Quality: Each design built in the lab would also be verified, tested, and fed back to improve the next without trading speed for scientific rigor.
• Sustainability: Over time, this approach is expected to complement traditional immunization-based methods used in the discovery of antibodies and other research tools.

“The autonomous lab reflects the kind of progress Danaher is uniquely positioned to deliver,” says Julie Sawyer Montgomery, Danaher president and CEO. “By applying our science, technology, and culture of continuous improvement, we can help turn promising ideas into validated systems faster. It’s an important step toward a future where AI, automation, and intelligent systems dramatically accelerate the journey from discovery to impact.”

Based at Abcam, a Danaher company, the lab uses AI to help create new affinity reagents, including antibodies, then builds and tests each one, feeding every result back into the model to improve the next design. The lab brings together industry-leading technologies and expertise from several Danaher operating companies, including Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies, and Molecular Devices, in one connected workflow.

The device orchestration and robotic automation is the result of collaborative work with Automata (Automata received an investment from DHR in January 2026). This continuous design-make-test-learn loop can run in a fraction of the time it takes today without trading speed for scientific rigor. This approach applies the same test-and-verify discipline of continuous improvement long used in Danaher operations to an AI-enabled laboratory environment. The lab is set to be an early proof point for how Danaher’s smart instruments, AI-ready data, and expert agentic systems can accelerate scientific discovery and medical progress.

Danaher senior vice president and chief science officer J. C. Gutierrez-Ramos says, “This lab represents a new model for scientific discovery where AI, automation, and human expertise work together in a continuous learning cycle. Speed is what supercharges that cycle. Every result sharpens the next design, so the faster each loop runs, the faster discovery compounds. The lab is designed to deliver up to eight times faster progress from idea to validated reagent, and up to a tenfold increase in reagent generation, while scientists continue to make the key decisions. That frees them to focus on the complex scientific challenges where human insight matters most.”

The lab is an example of a broader program within Danaher intended to create a fleet of smart instruments that are easier to integrate and control programmatically, produce AI-ready data, and include expert-level agentic systems designed to simplify operation, improve data quality, and generate deeper insights.

These intelligent devices can then be connected to create integrated workflows and autonomous labs that execute design-make-test-learn cycles. The approach also supports a shift toward more predictive and standardized research workflows, with models helping to prioritize the most promising designs before they are made, and robotics supporting more consistent experimentation.

The platform reflects an important milestone in Danaher’s continued investment in connected science at a global scale—technologies designed to help researchers move from scientific question to validated answer with greater speed, consistency, and confidence.